Kate Bingham is the former Chair of the UK Vaccine Taskforce, where she led a team of world-class experts from across industry, science, academia and government with the shared purpose of finding and manufacturing COVID-19 vaccines. The Taskforce helped place the UK at the leading edge of the international effort to fight the pandemic and it was the first Western country to start vaccination in December 2020. Kate was awarded a DBE in the Queen’s Birthday Honours in June 2021 for services to the procurement, manufacture and distribution of COVID-19 vaccines.
Kate has worked in the biotech sector for 30 years and is Managing Partner at life sciences venture capital firm SV Health Investors. She co-leads SV’s biotech franchise which has a long history of building high value, successful new companies developing transformational new medicines and bringing drugs from discovery to market.
Kate’s investments, many of which are examples of SV’s company creation approach to biotech investing, have resulted in the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer.
Kate is a board member of the Francis Crick Institute. She has a first class degree in Biochemistry from the University of Oxford and an MBA from Harvard Business School (Baker Scholar).
Kate advocates for more women in c-suite and board roles in biotech companies and in science generally.